DCN Dx has received a growth equity investment from Martis Capital
DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.
DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.
One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.
Talk to the deal team
Bradford A. Adams
Managing Director
Boston, United StatesOaklins TM Capital
Michael S. Goldman
Managing Director
New York, United StatesOaklins TM Capital
James McLaren
Managing Director
New York, United StatesOaklins TM Capital
Related deals
VHZ Group has been acquired by Gilde Equity Management and VHZ Group’s management
VHZ Group, the market leader in the Dutch B2B uPVC windows and doors market, has been acquired by Gilde Equity Management (GEM) together with the company’s management. With the acquisition, VHZ Group and GEM will be able to further expand on the company’s strategy and vision.
Learn moreBee2Link has acquired Terranova Web Systems
Bee2Link (B2L), the leading provider of software-as-a-service (SaaS) solutions to the automotive industry in France, has acquired Terranova Web Systems.
Learn moreAET Technologies has been acquired by Yotta Capital Partners
The CEO and management team of AET Technologies have sold the company to Yotta Capital Partners.
Learn more